Left ventricular hypertrophy is a leading risk factor for cardiovascular morbidity and mortality.
Although reverse ventricular remodelling was long thought to be irreversible, evidence from …

Aims To examine the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on
cardiac remodelling in patients with type 2 diabetes mellitus (T2DM) and/or heart failure …

Hypertension is a leading cause of heart failure and other cardiovascular diseases. Its role
in the pathogenesis of heart failure with reduced ejection fraction (HFrEF) differs from that in …

Background: Sacubitril/valsartan was demonstrated to reduce hospitalization rate and
mortality in patients with heart failure with reduced ejection fraction. Data on the effects of …

The renin-angiotensin-aldosterone system (RAAS) plays a major role in cardiovascular
health and disease. Short-term RAAS activation controls water and salt retention and causes …

The change in Gibbs energy when an ion or molecule moves from a vacuum to a solvent is
known as solvation energy and solvation is the process of attracting and associating …

Diabetic cardiomyopathy (DCM) is a chronic complication of diabetes that emphasizes the
urgency of developing new drug therapies. With an illustrious history in traditional medicine …

Angiotensin receptor-neprilysin inhibitor (ARNI) and sodium–glucose co-transporter-2
inhibitor (SGLT2i) have shown benefits in diabetic patients with heart failure with reduced …

Heart failure (HF) is an underappreciated complication of diabetes. HF occurs in individuals
with diabetes at higher rates, even in the absence of other HF risk factors such as coronary …

Heart failure is a serious threat to human health, with morbidity and mortality rates
increasing despite the existence of multiple treatment options. Therefore, it is necessary to …